Tumor Microenvironment Characterization in Triple-negative Breast Cancer Identifies Prognostic Gene Signature

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2021 Feb 4

PMID 33536349

Citations 8

Authors

Yan Qin

Jiehua Deng

Lihua Zhang

Jiaxing Yuan

Huawei Yang

Qiuyun Li

Affiliations

Soon will be listed here.

Abstract

We aimed to elucidate the landscape of tumor microenvironment (TME) in triple-negative breast cancer (TNBC). Cohorts from Gene Expression Omnibus database (N = 107) and METABRIC (N = 299) were used as the training set and validation set, respectively. TME was evaluated via single-sample gene set enrichment analysis, and unsupervised clustering was used for cluster identification. Consequently, TNBC was classified into two distinct TME clusters (Cluster 1 and Cluster 2) according to predefined immune-related terms. Cluster 1 was characterized by low immune infiltration with poor prognosis; whereas, Cluster 2 was characterized by high immune infiltration with better survival probability. Further, Cluster 1 had larger tumor volumes, while Cluster 2 had smaller tumor volumes. Finally, a TME signature for prognosis stratification in TNBC was developed and validated. In summary, we comprehensively evaluated the TME of TNBC and constructed a TME signature that correlated with prognosis. Our results provide new insights for the immunotherapy of TNBC.

Citing Articles

Tailored therapies for triple-negative breast cancer: current landscape and future perceptions.

Khan Y, Rizvi S, Raza A, Khan A, Hussain S, Khan N Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40029385 DOI: 10.1007/s00210-025-03896-4.

Machine learning unveils immune-related signature in multicenter glioma studies.

Yang S, Wang X, Huan R, Deng M, Kong Z, Xiong Y iScience. 2024; 27(4):109317.

PMID: 38500821 PMC: 10946333. DOI: 10.1016/j.isci.2024.109317.

Inhibition of TNBC Cell Growth by Paroxetine: Induction of Apoptosis and Blockage of Autophagy Flux.

Huang Q, Wu M, Pu Y, Zhou J, Zhang Y, Li R Cancers (Basel). 2024; 16(5).

PMID: 38473249 PMC: 10930888. DOI: 10.3390/cancers16050885.

A prognostic mathematical model based on tumor microenvironment-related genes expression for breast cancer patients.

Chen H, Wang S, Zhang Y, Gao X, Guan Y, Wu N Front Oncol. 2023; 13:1209707.

PMID: 37860187 PMC: 10583559. DOI: 10.3389/fonc.2023.1209707.

Identification and panoramic analysis of drug response-related genes in triple negative breast cancer using as an example NVP-BEZ235.

Feng J, Wang L, Zhang K, Ni S, Li B, Liu J Sci Rep. 2023; 13(1):5984.

PMID: 37045929 PMC: 10097725. DOI: 10.1038/s41598-023-32757-4.

References

Baeuerle P, Reinhardt C . Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009; 69(12):4941-4. DOI: 10.1158/0008-5472.CAN-09-0547. View

Johnson W, Li C, Rabinovic A . Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2006; 8(1):118-27. DOI: 10.1093/biostatistics/kxj037. View

Marra A, Viale G, Curigliano G . Recent advances in triple negative breast cancer: the immunotherapy era. BMC Med. 2019; 17(1):90. PMC: 6507064. DOI: 10.1186/s12916-019-1326-5. View

Ferrata M, Schad A, Zimmer S, Musholt T, Bahr K, Kuenzel J . PD-L1 Expression and Immune Cell Infiltration in Gastroenteropancreatic (GEP) and Non-GEP Neuroendocrine Neoplasms With High Proliferative Activity. Front Oncol. 2019; 9:343. PMC: 6514221. DOI: 10.3389/fonc.2019.00343. View

Rades D, Haus R, Janssen S, Schild S . An easy-to-use scoring system to estimate the survival of patients irradiated for bone metastases from lung cancer. Transl Lung Cancer Res. 2020; 9(4):1067-1073. PMC: 7481577. DOI: 10.21037/tlcr-19-642. View

Yin J, Fu W, Dai L, Jiang Z, Liao H, Chen W . ANKRD22 promotes progression of non-small cell lung cancer through transcriptional up-regulation of E2F1. Sci Rep. 2017; 7(1):4430. PMC: 5493668. DOI: 10.1038/s41598-017-04818-y. View

Speetjens F, Kuppen P, Sandel M, Menon A, Burg D, van de Velde C . Disrupted expression of CXCL5 in colorectal cancer is associated with rapid tumor formation in rats and poor prognosis in patients. Clin Cancer Res. 2008; 14(8):2276-84. DOI: 10.1158/1078-0432.CCR-07-4045. View

Mohme M, Riethdorf S, Pantel K . Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape. Nat Rev Clin Oncol. 2016; 14(3):155-167. DOI: 10.1038/nrclinonc.2016.144. View

Wang C, Kar S, Lai X, Cai W, Arfuso F, Sethi G . Triple negative breast cancer in Asia: An insider's view. Cancer Treat Rev. 2017; 62:29-38. DOI: 10.1016/j.ctrv.2017.10.014. View

10.

Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf A . Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013; 39(4):782-95. DOI: 10.1016/j.immuni.2013.10.003. View

11.

Huang X, Liu J, Wu G, Chen S, Jeen Pc F, Xie W . Development and Validation of a Nomogram for Preoperative Prediction of Perineural Invasion in Colorectal Cancer. Med Sci Monit. 2019; 25:1709-1717. PMC: 6415589. DOI: 10.12659/MSM.914900. View

12.

Wein L, Loi S . Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC). Breast. 2017; 34 Suppl 1:S27-S30. DOI: 10.1016/j.breast.2017.06.023. View

13.

Meyers B, Cosby R, Quereshy F, Jonker D . Adjuvant Chemotherapy for Stage II and III Colon Cancer Following Complete Resection: A Cancer Care Ontario Systematic Review. Clin Oncol (R Coll Radiol). 2017; 29(7):459-465. DOI: 10.1016/j.clon.2017.03.001. View

14.

Newman A, Steen C, Liu C, Gentles A, Chaudhuri A, Scherer F . Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019; 37(7):773-782. PMC: 6610714. DOI: 10.1038/s41587-019-0114-2. View

15.

Oliveira-Pinto S, Pontes O, Baltazar F, Costa M . In vivo efficacy studies of chromene-based compounds in triple-negative breast cancer - A systematic review. Eur J Pharmacol. 2020; 887:173452. DOI: 10.1016/j.ejphar.2020.173452. View

16.

Liu J, Huang X, Yang W, Li C, Li Z, Zhang C . Nomogram for predicting overall survival in stage II-III colorectal cancer. Cancer Med. 2020; 9(7):2363-2371. PMC: 7131840. DOI: 10.1002/cam4.2896. View

17.

Chen X, Shao Q, Hao S, Zhao Z, Wang Y, Guo X . CTLA-4 positive breast cancer cells suppress dendritic cells maturation and function. Oncotarget. 2017; 8(8):13703-13715. PMC: 5355131. DOI: 10.18632/oncotarget.14626. View

18.

Drouin M, Saenz J, Chiffoleau E . C-Type Lectin-Like Receptors: Head or Tail in Cell Death Immunity. Front Immunol. 2020; 11:251. PMC: 7040094. DOI: 10.3389/fimmu.2020.00251. View

19.

Mo X, Huang X, Feng Y, Wei C, Liu H, Ru H . Immune infiltration and immune gene signature predict the response to fluoropyrimidine-based chemotherapy in colorectal cancer patients. Oncoimmunology. 2020; 9(1):1832347. PMC: 7575007. DOI: 10.1080/2162402X.2020.1832347. View

20.

Chamoto K, Al-Habsi M, Honjo T . Role of PD-1 in Immunity and Diseases. Curr Top Microbiol Immunol. 2017; 410:75-97. DOI: 10.1007/82_2017_67. View